

IBA Lifesciences GmbH

Rudolf-Wissell-Str. 28 37079 Goettingen Germany

Tel.: +49 (0) 551-5 06 72-0

E-mail: info@iba-lifesciences.com www.iba-lifesciences.com

Data Sheet

pCSG-IBA43

Cat. No.: 5-5043-001

Version: 3.0

Revision Date: 28.07.2021

Description	StarGate Acceptor Vector for transient expression as well as for generation of stable mammalian cell lines. Extrachromosomal replication in mammalian cells could occur either by origin of replication from Epstein-Barr Virus (oriP) or by SV40 ori. For the former the vector provides the EBNA-1 gene and for the latter the cell line has to be latently infected with SV40 or express the SV40 large T antigen (e.g., HEK293T, COS-1, COS-7). Stable cell lines can be selected by the neomycin resistance gene (NeoR). In addition, the human cytomegalovirus (CMV) immediate-early promoter enables a high-level expression in a wide range of mammalian cells. The expressed recombinant protein will be localized in the cytoplasm.			
Affinity tag	Strep-tag®II is fused to the C-terminus and 6xHistidine-tag is fused to the N-terminus of the recombinant protein.			
Cloning Strategy	Cloning into StarGate Acceptor Vectors has to be done with the restriction enzyme Esp3I. There is no Multiple Cloning Site (MCS) available that can be used for the integration of the gene of interest instead (see manual).			
Resistance	Ampicillin: for selection of transformed E. coli cells Neomycin: for selection of stable cell lines			
Form	5 μg, dissolved in 20 μl TE buffer, pH 8.0: 10 mM Tris/HCl, 1 mM EDTA			
Concentration	250 ng/μl			
Stability	12 months after shipping			
Storage	recommended: 2-8 °C for frequent usage, -20 °C for long-term storage			
Shipping	room temperature			
Hazards	Product is not classified as hazardous according to (EC) No 1272/2008 [CLP]. A Material Safety Data Sheet is provided.			

For research use only


Trademark information

The owners of trademarks marked by """ or "TM" are identified at http://www.iba-lifesciences.com/patents.html. Registered names, trademarks, etc. used in this document, even when not specifically marked as such, are not to be considered unprotected by law.

Important licensing information

This product is covered by intellectual property (IP) rights and on completion of the sale IBA Lifesciences grants respective Limited Use Label Licenses to purchaser. IP rights and Limited Use Label Licenses for said technology are further described and identified at http://www.iba-lifesciences.com/patents.html or upon inquiry at info@iba-lifesciences.com or at IBA Lifesciences GmbH, Rudolf-Wissell-Str. 28, 37079 Goettingen, Germany. By use of this product the purchaser accepts the terms and conditions of all applicable Limited Use Label Licenses.

Expression cassette of pCSG-IBA43



expr. cass.

LacF

cP/Z cassette =	contains LacZ alpha fragment under control of a separate promoter, which allows alpha complementation of <i>LacZ</i> mutations such as <i>LacZΔM15</i> as in <i>E. coli</i> DH5α or TOP10.	The opposite of the state of th
ur protein =	as Laczamia as in E. con DHSd of TOP10. after StarGate cloning using Esp3I your gene of interest will be located here	pCSG-IBA
		FBNA.7

Features	from bp	to bp	Sequencing primer
polyA signal sequence	1	213	ESG/CSG-Primer-for
f1 origin	259	687	
SV40 ori	692	1035	5'- GAGAACCCACTGCTTACTGGC -3'
Neomycin resistance gene	1097	1891	
ColEI ori	2637	3222	FSC/CSC Primary
Ampicillin resistance gene	4253	3393	ESG/CSG-Primer-rev
EBNA-1	4944	6869	5'- TAGAAGGCACAGTCGAGG -3'
oriP, episomal replication origin	7170	9145	
CMV promoter	9426	10013	
forward primer binding site	10026	10046	
6xHistidine-tag	10089	10124	
LacZ alpha fragment	10350	10751	
Strep-tag®II	10815	10847	
reverse primer binding site	10909	10926	
total vector length		10926	